Debug Log
loading content...0%

PTC Degree Module 09: Landmark trials of Deflazacort in DMD: Study 1 and Study 2
Help
Print
References
Glossary
Home
This is Frame Title
This is Module Title
Click for
Help
Click for
Print PDF
Click for
References Popup
Click for
Glossary Popup
Click for
goto Home
Click for
Play/Pause
Click for
Replay
Player Bar
Click for
Previous frame
Click for
Next frame
Click for
Transcript Popup
Return to the Module
For Internal use only. This training material is for educational purposes only. It is not to be used, shared, or discussed with customers.
Please rotate your device 90° to landscape view.
GLOSSARY
X
Select a term from the list on the left
REFERENCES
X
  1. FDA press release. FDA Web site. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm540945.htm. Accessed 2 May 2018.
  2. Emflaza [Prescribing Information]. Northbrook, IL: Marathon Pharmaceuticals, LLC.2017.
  3. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:1-9.
  4. MRC Muscle scale. https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/. Accessed 9th July 2018.
  5. Neurology data supplement. Neurology Web site. http://n.neurology.org/content/neurology/suppl/2016/08/26/WNL.0000000000003217.DC1/e-figures.pdf. Accessed 2 May 2018.
  6. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994;17(4):386-391.
loading content...
Printable Training Module